On April 17, 2019 Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, reported completion of the acquisition of Osiris Therapeutics, Inc. for $19.00 per share in cash, representing a total equity value of approximately $660 million. Osiris is a fast growing company delivering regenerative medicine products including skin, bone graft and articular cartilage substitutes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The acquisition is expected to accelerate growth from Smith & Nephew’s Advanced Wound Management franchise.

Osiris delivered revenue of $142.8 million for the year ended 31 December 2018, a 20.5% increase over the prior year.

(Press release, Osiris Therapeutics, APR 17, 2019, View Source [SID1234670337])